The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACRS | -5.31% | -43.69% | -10.84% | -79% |
| S&P | +12.65% | +91.73% | +13.89% | +237% |
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
A bull on the company became more positive on its prospects.
Investors were cheered by the latest laboratory news from the company.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.30M | -24.1% |
| Gross Profit | $0.85M | -56.1% |
| Gross Margin | 19.40% | -25.2% |
| Market Cap | $205.83M | 150.9% |
| Market Cap / Employee | $3.22M | 0.0% |
| Employees | 64 | -29.7% |
| Net Income | -$14.61M | -92.6% |
| EBITDA | -$17.05M | -80.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.26M | -47.0% |
| Accounts Receivable | $4.68M | 1264.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.71M | -23.8% |
| Short Term Debt | $0.53M | 14.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -79.17% | -60.7% |
| Return On Invested Capital | -65.61% | 14.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.96M | -149.8% |
| Operating Free Cash Flow | -$10.93M | -149.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.36 | 1.06 | 1.07 | 1.56 | 147.61% |
| Price to Sales | 12.63 | 10.53 | 10.37 | 14.80 | 388.22% |
| Price to Tangible Book Value | 1.36 | 1.06 | 1.07 | 1.56 | 147.61% |
| Enterprise Value to EBITDA | -9.00 | -4.84 | -4.59 | -3.99 | -187.78% |
| Return on Equity | -84.5% | -91.0% | -101.4% | -113.2% | 338.31% |
| Total Debt | $2.60M | $2.48M | $2.37M | $2.24M | -17.20% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
